Global Cancer Biological Therapy Market
Market Size in USD Billion
CAGR :
% 
USD
98.00 Billion
USD
181.39 Billion
2021
2029
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 98.00 Billion |
 Market Size (Forecast Year) |
USD 181.39 Billion |
 CAGR |
% |
| Major Markets Players |
|
Global Cancer Biological Therapy Market, By Type (Monoclonal Antibodies, Vaccines, Cancer Growth Blockers, Cytokine, Others), Route of Administration (Intravenous, Subcutaneous, Intramuscular, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Cancer Biological Therapy Market Analysis and Size
The global cancer biological therapy market is expected to witness significant growth during the forecast period. The growing number of cancer cases and the increasing number of special cancer treatment facilities worldwide are expected to help expand the global cancer biological therapy market. Several specialists in the cancer biological therapy market are focusing towards the utilization of nanotechnology to offer development therapy to patients. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global cancer biological therapy market in the forecast period 2022-2029. The expected CAGR of global cancer biological therapy market is tend to be around 8% in the mentioned forecast period. The market was valued at USD 98 billion in 2021, and it would grow upto USD 181.39 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Biological therapy is cancer treatment that uses the body's immune system to fight against cancerous cells without affecting the healthy cells. The biological drug therapy such as monoclonal antibodies exerts their action by either hindering the cancer growth or rise cell death. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Cancer Biological Therapy Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Monoclonal Antibodies, Vaccines, Cancer Growth Blockers, Cytokine, Others), Route of Administration (Intravenous, Subcutaneous, Intramuscular, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Endo Pharmaceuticals plc (Ireland), Zydus Group (India), Bausch Health Companies Inc. (Canada) |
|
Market Opportunities |
|
Global Cancer Biological Therapy Market Dynamics
Drivers
- Increase in Cancer Cases
The rise in cancer cases globally boosts the global cancer biological therapy market in the forecast period As per the reports of the American Cancer Society Statistics in 2016, majority of cases of SCLC mostly occur in individuals between the age group of 60-80 years with an estimated global death rate being 30,000 per year. In addition to this, as per the reports of WHO, lung cancer is the second most dominant cancer in men and women causing 1.59 million deaths in 2012. This boost the market growth.
- Rising Healthcare Awareness
Awareness among patients as well as healthcare providers about the incidence of cancer is on the rise. Patients and doctors are now more actively participating in learning about the therapies available for treating these severe diseases. This is one of the most important drivers in the market. This creates more opportunity in the market.
Opportunities
- Patent Expiration Encourages New Launches
The patent expiration of several previous companies can create enhanced opportunities for the new market players. The wide adoption of combination therapies is a major factor contributing to the growth of the cancer biological therapy market. Additionally, R&D fundings are an add-on to the market.
- Development of Diversified Treatments
Researchers in the cancer biological therapy market primarily focus on the use of nanotechnology to offer advanced treatment to patients. Nanotechnology has the utmost potential to help in the cancer diagnosis. Furthermore, protein engineering and materials science advances are expected to help medical professionals target cancer cells more precisely. This is anticipated to provide new hope to cancer patients.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global cancer biological therapy market over a forecast period.
- Increasing Cost Of Treatments
The huge expenditure required for the treatment methods surely hamper the market growth. Many of the treatments involved in this disease require high cost and thus at times gets difficult for many people, especially the ones in the rural areas. Thus, this can act as a major hindrance factor for the market.
This global cancer biological therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cancer biological therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Cancer Biological Therapy Market Scope
The global cancer biological therapy market is segmented on the basis of type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Monoclonal Antibodies
- Vaccines
- Cancer Growth Blockers
- Cytokine
- Others
Route of Administration
- Intravenous
- Subcutaneous
- Intramuscular
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Cancer Biological Therapy Market Regional Analysis/Insights
The global cancer biological therapy market is analysed and market size insights and trends are provided by type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global cancer biological therapy market are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to have the highest market growth due to the increase prevalence of cancer, high demand of biological therapies and advanced healthcare facilities.
North America dominates the market due to the increase awareness about the diseases and rapidly disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Cancer Biological Therapy Market Share Analysis
The global cancer biological therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global cancer biological therapy market
Key players operating in the global cancer biological therapy market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Endo Pharmaceuticals plc (Ireland)
- Zydus Group (India)
- Bausch Health Companies Inc. (Canada)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CANCER BIOLOGICAL THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CANCER BIOLOGICAL THERAPY MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
5.3 GLOBAL CANCER BIOLOGICAL THERAPY MARKET ANALYSIS
6 EPIDEMOLOGY
6.1 EPIDEMOLOGY OF CANCER
7 INDUSTRY INSIGHTS
7.1 DEMOGRAPHIC TRENDS
7.2 KEY PRICING STRATEGIES
7.3 KEY PATIENT ENROLLMENT STRATEGIES
7.4 INTERVIEWS WITH MANUFACTURING COMPANIES
7.5 OTHER KOL SNAPSHOTS
8 REGULATORY FRAMWORK
9 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY TYPE
9.1 OVERVIEW
9.2 MONOCLONAL ANTIBODIES
9.2.1 NAKED MONOCLONAL ANTIBODIES
9.2.1.1. MARKET VALUE (USD)
9.2.1.2. MARKET VOLUME (IU)
9.2.1.3. ASP (USD)
9.2.2 CONJUGATED MONOCLONAL ANTIBODIES
9.2.2.1. RADIOLABELED ANTIBODIES
9.2.2.1.1. MARKET VALUE (USD)
9.2.2.1.2. MARKET VOLUME (IU)
9.2.2.1.3. ASP (USD)
9.2.2.2. ANTIBODY-DRUG CONJUGATES (CHEMOLABELED ANTIBODIES):
9.2.2.2.1. MARKET VALUE (USD)
9.2.2.2.2. MARKET VOLUME (IU)
9.2.2.2.3. ASP (USD)
9.2.3 BISPECIFIC MONOCLONAL ANTIBODIES
9.2.3.1. MARKET VALUE (USD)
9.2.3.2. MARKET VOLUME (IU)
9.2.3.3. ASP (USD)
9.3 CYTOKINES
9.4 VACCINES
9.4.1 PROPHYLACTIC VACCINES
9.4.1.1. MARKET VALUE (USD)
9.4.1.2. MARKET VOLUME (IU)
9.4.1.3. ASP (USD)
9.4.2 THERAPEUTIC VACCINES
9.4.2.1. MARKET VALUE (USD)
9.4.2.2. MARKET VOLUME (IU)
9.4.2.3. ASP (USD)
9.5 CHECKPOINT INHIBITORS
9.5.1 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4)
9.5.1.1. MARKET VALUE (USD)
9.5.1.2. MARKET VOLUME (IU)
9.5.1.3. ASP (USD)
9.5.2 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1)
9.5.2.1. MARKET VALUE (USD)
9.5.2.2. MARKET VOLUME (IU)
9.5.2.3. ASP (USD)
9.5.3 TF INHIBITOR
9.5.3.1. MARKET VALUE (USD)
9.5.3.2. MARKET VOLUME (IU)
9.5.3.3. ASP (USD)
9.6 CELL THERAPIES
9.6.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY
9.6.2 DENDRITIC CELLS
9.6.3 TIL THERAPY
9.6.4 TCR THERAPY
9.6.5 NK CELL THERAPY
9.7 IMMUNOMODULATORS
9.7.1 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
9.7.1.1. MARKET VALUE (USD)
9.7.1.2. MARKET VOLUME (IU)
9.7.1.3. ASP (USD)
9.7.2 INTERFERONS
9.7.2.1. MARKET VALUE (USD)
9.7.2.2. MARKET VOLUME (IU)
9.7.2.3. ASP (USD)
9.7.3 INTERLEUKINS
9.7.3.1. MARKET VALUE (USD)
9.7.3.2. MARKET VOLUME (IU)
9.7.3.3. ASP (USD)
9.8 ONCOLYTIC VIRUS
9.8.1.1. MARKET VALUE (USD)
9.8.1.2. MARKET VOLUME (IU)
9.8.1.3. ASP (USD)
10 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 LUNG CANCER
10.2.1 MONOCLONAL ANTIBODIES
10.2.2 VACCINES
10.2.3 CHECKPOINT INHIBITORS
10.2.4 CELL THERAPIES
10.2.5 IMMUNOMODULATORS
10.2.6 ONCOLYTIC VIRUS
10.2.7 CYTOKINES
10.3 BREAST CANCER
10.3.1 MONOCLONAL ANTIBODIES
10.3.2 VACCINES
10.3.3 CHECKPOINT INHIBITORS
10.3.4 CELL THERAPIES
10.3.5 IMMUNOMODULATORS
10.3.6 ONCOLYTIC VIRUS
10.3.7 CYTOKINES
10.4 MULTIPLE MYELOMA
10.4.1 MONOCLONAL ANTIBODIES
10.4.2 VACCINES
10.4.3 CHECKPOINT INHIBITORS
10.4.4 CELL THERAPIES
10.4.5 IMMUNOMODULATORS
10.4.6 ONCOLYTIC VIRUS
10.4.7 CYTOKINES
10.5 COLORECTAL CANCER
10.5.1 MONOCLONAL ANTIBODIES
10.5.2 VACCINES
10.5.3 CHECKPOINT INHIBITORS
10.5.4 CELL THERAPIES
10.5.5 IMMUNOMODULATORS
10.5.6 ONCOLYTIC VIRUS
10.5.7 CYTOKINES
10.6 HEAD & NECK CANCER
10.6.1 MONOCLONAL ANTIBODIES
10.6.2 VACCINES
10.6.3 CHECKPOINT INHIBITORS
10.6.4 CELL THERAPIES
10.6.5 IMMUNOMODULATORS
10.6.6 ONCOLYTIC VIRUS
10.6.7 CYTOKINES
10.7 PROSTATE CANCER
10.7.1 MONOCLONAL ANTIBODIES
10.7.2 VACCINES
10.7.3 CHECKPOINT INHIBITORS
10.7.4 CELL THERAPIES
10.7.5 IMMUNOMODULATORS
10.7.6 ONCOLYTIC VIRUS
10.7.7 CYTOKINES
10.8 MELANOMA
10.8.1 MONOCLONAL ANTIBODIES
10.8.2 VACCINES
10.8.3 CHECKPOINT INHIBITORS
10.8.4 CELL THERAPIES
10.8.5 IMMUNOMODULATORS
10.8.6 ONCOLYTIC VIRUS
10.8.7 CYTOKINES
10.9 OVARIAN CANCER
10.9.1 MONOCLONAL ANTIBODIES
10.9.2 VACCINES
10.9.3 CHECKPOINT INHIBITORS
10.9.4 CELL THERAPIES
10.9.5 IMMUNOMODULATORS
10.9.6 ONCOLYTIC VIRUS
10.9.7 CYTOKINES
10.1 CERVICAL CANCER
10.10.1 MONOCLONAL ANTIBODIES
10.10.2 VACCINES
10.10.3 CHECKPOINT INHIBITORS
10.10.4 CELL THERAPIES
10.10.5 IMMUNOMODULATORS
10.10.6 ONCOLYTIC VIRUS
10.10.7 CYTOKINES
10.11 STOMACH CANCER
10.11.1 MONOCLONAL ANTIBODIES
10.11.2 VACCINES
10.11.3 CHECKPOINT INHIBITORS
10.11.4 CELL THERAPIES
10.11.5 IMMUNOMODULATORS
10.11.6 ONCOLYTIC VIRUS
10.11.7 CYTOKINES
10.12 OTHERS
11 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.2.1 AGE LESS THAN 20 YRS
11.2.2 21-40 YRS
11.2.3 ABOVE 40 YRS
11.3 FEMALE
11.3.1 AGE LESS THAN 20 YRS
11.3.2 21-40 YRS
11.3.3 ABOVE 40 YRS
12 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY FORM
12.1 OVERVIEW
12.2 ORAL
12.3 INTRAVENOUS (IV)
12.4 TOPICAL
12.5 INTRAVESICAL
13 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY DRUG TYPE
13.1 OVERVIEW
13.2 BRANDED
13.2.1 ZEVALIN
13.2.2 ADCETRIS
13.2.3 KYMRIAH
13.2.4 YESCARTA
13.2.5 BREYANZI
13.2.6 KEYTRUDA
13.2.7 TECENTRIQ
13.2.8 OPDIVO
13.2.9 PROVENGE
13.2.10 BAVENCIO
13.3 BIOSIMILAR
14 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALITY CLINICS
14.4 CLINICS
14.5 ACADEMIC AND RESEARCH INSTITUTES
14.6 HOMECARE
14.7 OTHERS
15 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
15.3.1 HOSPITAL PHARMACY
15.3.2 RETAIL PHARMACY
15.3.3 ONLINE PHARMACY
16 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY REGION
GLOBAL CANCER BIOLOGICAL THERAPY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
16.2 EUROPE
16.2.1 GERMANY
16.2.2 U.K.
16.2.3 ITALY
16.2.4 FRANCE
16.2.5 SPAIN
16.2.6 RUSSIA
16.2.7 SWITZERLAND
16.2.8 TURKEY
16.2.9 BELGIUM
16.2.10 NETHERLANDS
16.2.11 DENMARK
16.2.12 SWEDEN
16.2.13 POLAND
16.2.14 NORWAY
16.2.15 FINLAND
16.2.16 REST OF EUROPE
16.3 ASIA-PACIFIC
16.3.1 JAPAN
16.3.2 CHINA
16.3.3 SOUTH KOREA
16.3.4 INDIA
16.3.5 SINGAPORE
16.3.6 THAILAND
16.3.7 INDONESIA
16.3.8 MALAYSIA
16.3.9 PHILIPPINES
16.3.10 AUSTRALIA
16.3.11 NEW ZEALAND
16.3.12 VIETNAM
16.3.13 TAIWAN
16.3.14 REST OF ASIA-PACIFIC
16.4 SOUTH AMERICA
16.4.1 BRAZIL
16.4.2 ARGENTINA
16.4.3 REST OF SOUTH AMERICA
16.5 MIDDLE EAST AND AFRICA
16.5.1 SOUTH AFRICA
16.5.2 EGYPT
16.5.3 BAHRAIN
16.5.4 UNITED ARAB EMIRATES
16.5.5 KUWAIT
16.5.6 OMAN
16.5.7 QATAR
16.5.8 SAUDI ARABIA
16.5.9 REST OF MIDDLE EAST AND AFRICA
16.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, COMPANY PROFILE
18.1 AMGEN
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 SPECTRUM PHARMACEUTICALS
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 F. HOFFMANN-LA ROCHE AG
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 BAYER AG
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 BRISTOL-MYERS SQUIBB
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 ELI LILLY AND COMPANY
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 JANSSEN BIOTECH, INC
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 MERCK & CO., INC.
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 NOVARTIS
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.1 PFIZER
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 GENENTECH, INC.
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 JUNO THERAPEUTICS
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 REGENERON PHARMACEUTICALS, INC.
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 CELLDEX THERAPEUTICS
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 KITE PHARMA
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 ATARA BIOTHERAPEUTICS
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 CELLECTIS
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 ASTRAZENECA
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 ABBVIE INC.
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
18.2 TAKEDA
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 GLAXOSMITHKLINE PLC.
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 MYLAN N.V.
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPMENTS
18.23 TEVA PHARMACEUTICAL INDUSTRIES LTD.
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPMENTS
18.24 ONO PHARMACEUTICAL CO., LTD.
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPMENTS
18.25 SANOFI
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPMENTS
18.26 SUN PHARMACEUTICAL INDUSTRIES LTD.
18.26.1 COMPANY OVERVIEW
18.26.2 REVENUE ANALYSIS
18.26.3 GEOGRAPHIC PRESENCE
18.26.4 PRODUCT PORTFOLIO
18.26.5 RECENT DEVELOPMENTS
18.27 AUROBINDO PHARMA
18.27.1 COMPANY OVERVIEW
18.27.2 REVENUE ANALYSIS
18.27.3 GEOGRAPHIC PRESENCE
18.27.4 PRODUCT PORTFOLIO
18.27.5 RECENT DEVELOPMENTS
18.28 INCYTE
18.28.1 COMPANY OVERVIEW
18.28.2 REVENUE ANALYSIS
18.28.3 GEOGRAPHIC PRESENCE
18.28.4 PRODUCT PORTFOLIO
18.28.5 RECENT DEVELOPMENTS
18.29 IMMUNITYBIO INC.
18.29.1 COMPANY OVERVIEW
18.29.2 REVENUE ANALYSIS
18.29.3 GEOGRAPHIC PRESENCE
18.29.4 PRODUCT PORTFOLIO
18.29.5 RECENT DEVELOPMENTS
18.3 GALECTIN THERAPEUTICS
18.30.1 COMPANY OVERVIEW
18.30.2 REVENUE ANALYSIS
18.30.3 GEOGRAPHIC PRESENCE
18.30.4 PRODUCT PORTFOLIO
18.30.5 RECENT DEVELOPMENTS
18.31 COMPUGEN
18.31.1 COMPANY OVERVIEW
18.31.2 REVENUE ANALYSIS
18.31.3 GEOGRAPHIC PRESENCE
18.31.4 PRODUCT PORTFOLIO
18.31.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 CONCLUSION
20 QUESTIONNAIRE
21 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
